Plasma Protein Therapeutics Market Size, Share, Industry Trends and Forecast to 2030

What is the Market Size & CAGR of Plasma Protein Therapeutics market in 2021?

The global plasma protein therapeutics market is expected to have a growth rate of 5.8% CAGR from 2021 to 2026. As a result, the market is anticipated to reach a value of USD 44.3 billion by 2026.

COVID-19 Impact on the Plasma Protein Therapeutics Market

The COVID-19 pandemic has had a mixed impact on the plasma protein therapeutics market. On one hand, the increased focus on healthcare and the treatment of various diseases has led to a surge in demand for plasma protein therapeutics. However, disruptions in the supply chain and restrictions on movement have affected the production and distribution of these therapies.

Plasma Protein Therapeutics Dynamics

Plasma protein therapeutics are bioengineered proteins derived from human plasma that are used to treat a variety of medical conditions. These therapies are crucial in the treatment of rare and chronic diseases such as hemophilia, immune deficiencies, and autoimmune disorders. The increasing prevalence of these diseases, coupled with advancements in biotechnology, is driving the growth of the plasma protein therapeutics market.

Segments and Related Analysis

The plasma protein therapeutics market can be segmented based on the type of therapy, including immunoglobulins, albumin, and clotting factors. Immunoglobulins are the largest segment, accounting for a significant portion of the market share. The increasing use of immunoglobulins in the treatment of autoimmune diseases and primary immunodeficiency disorders is driving the growth of this segment.

By Region Analysis

The plasma protein therapeutics market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market due to the presence of key players, advanced healthcare infrastructure, and high prevalence of chronic diseases. However, the Asia Pacific region is expected to witness significant growth due to increasing healthcare expenditure and growing awareness about plasma protein therapies.

Key Market Players and Competitive Landscape

Key players in the plasma protein therapeutics market include CSL Behring, Grifols, Octapharma, Kedrion, and Takeda Pharmaceutical Company. These companies are focusing on research and development to introduce innovative therapies and expand their product portfolio. The market is highly competitive, with companies engaging in strategic partnerships and acquisitions to gain a competitive edge.

Recent Happenings in the Plasma Protein Therapeutics Market

In recent years, the plasma protein therapeutics market has witnessed significant developments, including the launch of new therapies, FDA approvals, and strategic collaborations. For example, in 2020, CSL Behring received FDA approval for its plasma-derived therapy for the treatment of primary immunodeficiency disorders. Such advancements are expected to drive the growth of the market in the coming years.